Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA

Zhi Fu1, Guang Yang1, Tiezheng Wang1

  • 1General Surgery Center, Capital Medical University Youan Hospital, 100069 Beijing, P.R. China.

Insights

This study identified ten sorafenib-associated differentially expressed genes (SADs) in hepatocellular carcinoma (HCC). Three long non-coding RNAs (lncRNAs) were found to be independent predictors of patient survival, offering potential new therapeutic targets for HCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Hepatocellular carcinoma (HCC) is a major liver cancer subtype with limited treatment efficacy.
  • Current therapies like sorafenib offer modest survival benefits for HCC patients.
  • Understanding the molecular mechanisms underlying HCC and sorafenib response is crucial.

Purpose of the Study:

  • To investigate the expression profiles and regulatory networks of competitive endogenous RNAs (ceRNAs) for sorafenib-related target genes in HCC.
  • To identify novel prognostic biomarkers for HCC patients treated with sorafenib.
  • To explore the functional roles of identified genes in HCC development.

Main Methods:

  • Analysis of clinical and expression data from TCGA and GEO databases for HCC.
  • Identification of differentially expressed genes (DEGs) and sorafenib-associated DEGs (SADs).
  • Gene Set Enrichment Analysis (GSEA), ceRNA network construction, and Cox regression analysis.
  • Validation of prognostic lncRNAs and SADs expression using qRT-PCR.

Main Results:

  • Ten SADs were identified, with differential expression in HCC tissues.
  • GSEA revealed distinct functional categories for SADs.
  • A ceRNA network involving 49 lncRNAs, 14 miRNAs, and 8 mRNAs was constructed.
  • Three lncRNAs (SNHG7, GAS5, HCP5) were upregulated in HCC and identified as independent predictors of overall survival.

Conclusions:

  • Ten SADs were systematically identified, providing insights into HCC molecular mechanisms.
  • Prognostic lncRNAs were identified, highlighting their potential as therapeutic targets.
  • Further research into the ceRNA axis regulation of SADs and prognostic lncRNAs is warranted for HCC treatment development.